State Street SPDR S&P Pharmaceuticals ETF (XPH)

Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

President Donald Trump threatened 100% tariffs on some drug imports.

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.

The tariffs will impact products imported from Europe, the Trump administration said late Thursday.

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.

In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at the top echelons of the Danish drugmaker sent shockwaves through the investor community, wiping billions off its market capitalization and

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical products and cars most exposed.

The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S.

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities.

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.